|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 508.00 DKK | +0.43% |
|
-1.63% | -29.00% |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -30.08 | -34.28 | -28.21 | -19.93 | -13.81 | |||||
Return on Total Capital | -37.62 | -42.7 | -33.31 | -22.99 | -14.8 | |||||
Return On Equity % | -68.51 | -94.4 | -110.75 | -58.43 | -21.13 | |||||
Return on Common Equity | -68.51 | -94.4 | -110.75 | -58.43 | -21.13 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 74.37 | 59.39 | 100 | 99.07 | 87.44 | |||||
SG&A Margin | 132.51 | 217.47 | 259.18 | 62.99 | 644.47 | |||||
EBITDA Margin % | -224.3 | -350.07 | -698.78 | -161.83 | -2.01K | |||||
EBITA Margin % | -227.01 | -356.27 | -782.86 | -163.73 | -2.02K | |||||
EBIT Margin % | -228.95 | -358.96 | -782.86 | -163.73 | -2.02K | |||||
Income From Continuing Operations Margin % | -239.65 | -348.01 | -928.6 | -205.3 | -1.72K | |||||
Net Income Margin % | -239.65 | -348.01 | -1.16K | -205.3 | -1.72K | |||||
Net Avail. For Common Margin % | -239.65 | -348.01 | -928.6 | -205.3 | -1.72K | |||||
Normalized Net Income Margin | -151.25 | -217.56 | -498.09 | -100.91 | -1.13K | |||||
Levered Free Cash Flow Margin | -122.79 | -253.28 | -367.48 | -66.8 | -1.17K | |||||
Unlevered Free Cash Flow Margin | -122.27 | -252.4 | -334.03 | -62.37 | -1.16K | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.21 | 0.15 | 0.06 | 0.19 | 0.01 | |||||
Fixed Assets Turnover | 2.09 | 1.35 | 0.54 | 2.17 | 0.46 | |||||
Receivables Turnover (Average Receivables) | 14.96 | 4.9 | 0.77 | 2.88 | 0.43 | |||||
Inventory Turnover (Average Inventory) | - | 1.3 | - | 0.69 | 0.85 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 4 | 5.15 | 6.73 | 6.25 | 21.14 | |||||
Quick Ratio | 3.71 | 4.6 | 6.73 | 6.23 | 21.11 | |||||
Operating Cash Flow to Current Liabilities | -1.94 | -3.63 | -4.82 | -1.5 | -2.31 | |||||
Days Sales Outstanding (Average Receivables) | 24.47 | 74.55 | 472.24 | 126.7 | 850.51 | |||||
Days Outstanding Inventory (Average Inventory) | - | 281.82 | - | 526.71 | 433.05 | |||||
Average Days Payable Outstanding | - | 143 | - | 5.05K | 4.69K | |||||
Cash Conversion Cycle (Average Days) | - | 213.37 | - | -4.4K | -3.41K | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 10.58 | 84.87 | 64.23 | 7.49 | 4.55 | |||||
Total Debt / Total Capital | 9.57 | 45.91 | 39.11 | 6.96 | 4.35 | |||||
LT Debt/Equity | 9.44 | 83.26 | 62.43 | 6.44 | 4.36 | |||||
Long-Term Debt / Total Capital | 8.54 | 45.04 | 38.01 | 5.99 | 4.17 | |||||
Total Liabilities / Total Assets | 30.23 | 55.13 | 47.01 | 19.55 | 9.35 | |||||
EBIT / Interest Expense | -279.42 | -256.71 | -14.09 | -21.73 | -37.27 | |||||
EBITDA / Interest Expense | -269.07 | -246.87 | -12.32 | -20.95 | -36.6 | |||||
(EBITDA - Capex) / Interest Expense | -277.72 | -252.28 | -12.53 | -21.38 | -36.89 | |||||
Total Debt / EBITDA | -0.17 | -0.78 | -0.74 | -0.22 | -0.31 | |||||
Net Debt / EBITDA | 1.45 | 0.63 | 0.92 | 2.8 | 6.95 | |||||
Total Debt / (EBITDA - Capex) | -0.16 | -0.76 | -0.72 | -0.22 | -0.31 | |||||
Net Debt / (EBITDA - Capex) | 1.4 | 0.62 | 0.9 | 2.74 | 6.89 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 754.8 | -17.19 | -4.2 | 229.65 | -81.71 | |||||
Gross Profit, 1 Yr. Growth % | 542.14 | -33.87 | 6.57 | 226.58 | -83.86 | |||||
EBITDA, 1 Yr. Growth % | 35.91 | 29.24 | -5.46 | -23.96 | 126.88 | |||||
EBITA, 1 Yr. Growth % | 36.42 | 29.96 | 4.08 | -31.27 | 126.12 | |||||
EBIT, 1 Yr. Growth % | 37.59 | 29.83 | 4.08 | -31.27 | 126.12 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 48.15 | 20.24 | 27.91 | -27.12 | 53.3 | |||||
Net Income, 1 Yr. Growth % | 48.15 | 20.24 | 18.07 | -41.46 | 53.3 | |||||
Normalized Net Income, 1 Yr. Growth % | 47.54 | 19.1 | 10.03 | -33.42 | 104.65 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 30.51 | 7.61 | 18.68 | -40.5 | 30.58 | |||||
Accounts Receivable, 1 Yr. Growth % | 6.09K | 57.1 | -24.65 | 5.83 | 97.91 | |||||
Inventory, 1 Yr. Growth % | - | 82.1 | -98.91 | 517.03 | 34.82 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 69.97 | 3.95 | -25.27 | -9.45 | -16.42 | |||||
Total Assets, 1 Yr. Growth % | 10.16 | 17.35 | -25.53 | 28.59 | 380.08 | |||||
Tangible Book Value, 1 Yr. Growth % | -5.51 | -25.41 | -6.65 | 93.72 | 444.36 | |||||
Common Equity, 1 Yr. Growth % | -1.08 | -24.53 | -12.06 | 95.22 | 440.97 | |||||
Cash From Operations, 1 Yr. Growth % | 68.2 | 75.98 | -22.26 | -54.83 | 118.67 | |||||
Capital Expenditures, 1 Yr. Growth % | 19.05 | -11.62 | -47.09 | -4.01 | -10.57 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 36.6 | 70.81 | -35.2 | -40.38 | 221.6 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 36.9 | 70.93 | -40.84 | -38.8 | 240.95 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 205.01 | 166.05 | -26.41 | 77.71 | -22.35 | |||||
Gross Profit, 2 Yr. CAGR % | 175.49 | 106.07 | -26.41 | 86.56 | -27.39 | |||||
EBITDA, 2 Yr. CAGR % | 33.9 | 33.55 | 11.59 | -15.04 | 31.34 | |||||
EBITA, 2 Yr. CAGR % | 34.03 | 33.15 | 14.02 | -15.29 | 24.66 | |||||
EBIT, 2 Yr. CAGR % | 34.6 | 33.65 | 14.02 | -15.29 | 24.66 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 20.69 | 33.47 | 20.17 | -3.45 | 5.7 | |||||
Net Income, 2 Yr. CAGR % | 20.69 | 33.47 | 19.15 | -16.86 | -5.27 | |||||
Normalized Net Income, 2 Yr. CAGR % | 34.65 | 32.56 | 10.92 | -14.28 | 16.73 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 7.95 | 18.51 | 9.51 | -15.97 | -11.85 | |||||
Accounts Receivable, 2 Yr. CAGR % | 276.8 | 886.09 | 57.71 | -10.7 | 29.39 | |||||
Inventory, 2 Yr. CAGR % | - | - | -85.94 | -74.12 | 188.42 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 269.19 | 32.92 | -11.86 | -17.74 | -13 | |||||
Total Assets, 2 Yr. CAGR % | 19.7 | 13.7 | -6.52 | -2.14 | 148.46 | |||||
Tangible Book Value, 2 Yr. CAGR % | 2.46 | -16.05 | -16.56 | 34.48 | 224.74 | |||||
Common Equity, 2 Yr. CAGR % | 4.94 | -13.59 | -18.53 | 31.03 | 224.98 | |||||
Cash From Operations, 2 Yr. CAGR % | 22.17 | 72.05 | 16.96 | -40.74 | -0.61 | |||||
Capital Expenditures, 2 Yr. CAGR % | 149.04 | 2.57 | -31.62 | -28.73 | -7.34 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -35.98 | 52.75 | 5.63 | -37.69 | 38.47 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -36.19 | 52.97 | 5.57 | -39.66 | 44.46 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 37.36 | 97.5 | 36.01 | 21.31 | -16.72 | |||||
Gross Profit, 3 Yr. CAGR % | 29.08 | 71.21 | 36.46 | 20.93 | -17.49 | |||||
EBITDA, 3 Yr. CAGR % | 48.14 | 32.33 | 8.16 | -1.67 | 17.87 | |||||
EBITA, 3 Yr. CAGR % | 47.78 | 32.66 | 11.46 | -3.59 | 17.51 | |||||
EBIT, 3 Yr. CAGR % | 48.2 | 32.99 | 11.46 | -3.59 | 17.51 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 45.58 | 20.54 | 19.1 | 1.72 | 12.64 | |||||
Net Income, 3 Yr. CAGR % | 45.58 | 20.54 | 28.13 | -5.98 | 1.95 | |||||
Normalized Net Income, 3 Yr. CAGR % | 45.08 | 29.26 | 12.66 | -6.34 | 14.57 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 30.85 | 7.84 | 7.32 | -10.64 | -2.67 | |||||
Accounts Receivable, 3 Yr. CAGR % | 101.53 | 181.49 | 435.96 | 38.07 | 8.05 | |||||
Inventory, 3 Yr. CAGR % | - | - | - | -50.4 | -55.13 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 136.47 | 141.98 | 9.7 | -11.07 | -17.3 | |||||
Total Assets, 3 Yr. CAGR % | 34.68 | 18.91 | -1.26 | 3.97 | 66.28 | |||||
Tangible Book Value, 3 Yr. CAGR % | 31.56 | -7.83 | -13.03 | 10.49 | 114.32 | |||||
Common Equity, 3 Yr. CAGR % | 33.67 | -5.98 | -13.08 | 9.02 | 110.2 | |||||
Cash From Operations, 3 Yr. CAGR % | 35.19 | 37.97 | 32.02 | -14.82 | -8.42 | |||||
Capital Expenditures, 3 Yr. CAGR % | 51.33 | 76.32 | -17.74 | -23.43 | -23.13 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 47.56 | -11.21 | 6.36 | -12.56 | 7.68 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 51.05 | -11.38 | 3.25 | -11.81 | 7.47 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 13.49 | 4.85 | -5.27 | 55.27 | 8.69 | |||||
Gross Profit, 5 Yr. CAGR % | 9.7 | -2.77 | -3.17 | 57.88 | 6.02 | |||||
EBITDA, 5 Yr. CAGR % | 60.2 | 55.23 | 24.41 | 4.65 | 16.99 | |||||
EBITA, 5 Yr. CAGR % | 58.05 | 54.34 | 26.78 | 4.68 | 16.64 | |||||
EBIT, 5 Yr. CAGR % | 58.32 | 54.57 | 26.78 | 4.68 | 16.64 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 49.35 | 45.28 | 28.61 | 3.9 | 13.55 | |||||
Net Income, 5 Yr. CAGR % | 49.35 | 45.28 | 34.37 | 3.9 | 13.55 | |||||
Normalized Net Income, 5 Yr. CAGR % | 48.14 | 44.3 | 24.24 | 3.25 | 14.34 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 34.88 | 29.7 | 16.23 | -8.07 | -0.81 | |||||
Accounts Receivable, 5 Yr. CAGR % | -21.72 | 44.7 | 82.71 | 106.31 | 203.55 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 66.89 | 74.61 | 59.34 | 57.16 | -0.01 | |||||
Total Assets, 5 Yr. CAGR % | 22.6 | 24.38 | 16.38 | 9.99 | 42.82 | |||||
Tangible Book Value, 5 Yr. CAGR % | 35.96 | 25.73 | 9.65 | 7.2 | 47.31 | |||||
Common Equity, 5 Yr. CAGR % | 37.27 | 27.24 | 9.65 | 7.37 | 47.3 | |||||
Cash From Operations, 5 Yr. CAGR % | 25.1 | 96.95 | 27.58 | -1.6 | 17.85 | |||||
Capital Expenditures, 5 Yr. CAGR % | 44.03 | 53.47 | 10.14 | 22.72 | -13.73 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 18.11 | 50.55 | 23.13 | -26.38 | 18.32 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 20.2 | 45.63 | 22.61 | -27.42 | 18.23 |
- Stock Market
- Equities
- ZEAL Stock
- Financials Zealand Pharma A/S
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















